Cardiol Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2025 · Filed Mar 31, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Research Programs
Research Programs
Cardiol has assembled an international network of experts in the synthesis, formulation, pharmacology and testing of drugs. Cardiol has several research programs underway or completed with the following organizations:
| ● | Virginia Commonwealth University and University of Virginia |
| ● | The Houston Methodist DeBakey Heart & Vascular Center |
| ● | TecSalud del Tecnológico de Monterrey |
Due to the early stage of these research programs, the total costs and timing of these programs beyond the costs previously funded cannot be determined at this stage as they will depend on a variety of factors. Cardiol relies on researchers and clinicians, CROs, clinical data management organizations, and consultants to assist with the design, conduct, supervision, and monitoring of these research programs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.